

Oncology Research

Approved:	February 2023
Study:	Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients (MTG-022)
Investigators:	Paschal Wilson, MD (PI); Hematology and Oncology Group
Summary:	This study project involves minimal risk blood draw protocols.
Approved:	February 2024
Study:	An Observational Study Profiling Advanced Stage Breast Cancer Patients to Screen for Investigational Therapies
Investigator:	Paschal Wilson, MD (PI); Amit Jain, MD; Usman Khan, MD; Jiahuai Tan, MD
Summary:	The purpose of this in-house project is to match patients to relevant investigational therapies.
Approved:	April 2025
Study:	SUNRAY – A Global Pivotal Study in Participants with <i>KRAS</i> G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab versus Placebo and Pembrolizumab in those with PD-L1 Expression $\geq$ 50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum versus Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)
Investigators:	Amit Jain, MD (PI); Usman Khan, MD; Jiahuai Tan, MD; Paschal Wilson, MD
Summary:	The purpose of this study is to determine if adding olomorasib to standard of care treatment helps to control symptoms better and for a longer period of time in non-small cell lung cancer patients.